Secondary prevention of coronary heart disease in primary care

Journal of Clinical Governance

Volumn 9, Issue 4, 2001, Pages 211-222

  Enriquez Puga, A ^a   Khunti, K ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CELIPROLOL; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; INSULIN; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; OXPRENOLOL; PINDOLOL; PLACEBO; PRAVASTATIN; PROPRANOLOL; RAMIPRIL; SIMVASTATIN; TICLOPIDINE; TIMOLOL; UNINDEXED DRUG; XAMOTEROL;

BLOOD PRESSURE MEASUREMENT; BODY MASS; BRAIN HEMORRHAGE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG USE; EVIDENCE BASED MEDICINE; EXERCISE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MEDICAL AUDIT; MEDICAL RECORD; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REHABILITATION CENTER; REVIEW; RISK FACTOR; SCREENING; SECONDARY PREVENTION; SMOKING CESSATION; STROKE; SURVIVAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0035671030     PISSN: 14675277     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Secondary prevention in 24 431 patients with coronary heart disease: Survey in primary care
2. Secondary prevention in coronary heart disease: Baseline survey of provision in general practice
3. Effects of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): Randomised controlled trial
4. Prospective randomised controlled trial of methods of call and recall for cervical cytology screening
5. Do clinical guidelines introduced with practice-based education improve care of asthmatic and diabetic patients? A randomised controlled trial in general practices in East London
6. Secondary prevention clinics for coronary heart disease: Randomised trial of effect on health
7. Cluster randomised controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care
8. North of England Evidence-based Guidelines Development Project: Guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care
9. Aspirin and risk of haemorrhagic stroke: A meta-analysis of randomised controlled trials
10. Collaborative overview of randomised trials of antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
11. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
12. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial
13. Secondary prevention of coronary heart disease in primary care: A healthy heart initiative
14. Systematic review of studies of quality of clinical care in general practice in the UK, Australia and New Zealand
15. Improving aspirin prophylaxis after myocardial infarction in primary care: Collaboration in multipractice audit between primary care audit group and health authority
16. Total and cardiovascular mortality in relation to cigarette smoking, cerum cholesterol concentration, and diastolic blood pressure among black and white males followed up for five years
17. Blood pressure, stroke and coronary heart disease
18. Exercise radio-nuclide venticulographic responses in hypertensive patients with chest pain
19. Coronary heart disease in residents of Rochester, Minnesota, 1950-1975: Effect of hypertension and its treatment on survival of patients with coronary artery disease
20. Risk factors for long-term coronary prognosis after initial myocardial infarction: The Framingham Study
21. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension)
22. MRC trial on treatment of hypertension in older adults: Principal results
23. Joint British recommendations on prevention of coronary heart disease in clinical practice: Summary
24. β-Blockade during and after myocardial infarction: An overview of the randomised trials
25. β-Blockade after myocardial infarction: Systematic review and meta regression analysis
26. Rate of heart failure and 1-year survival for older people receiving low-dose β-blocker therapy after myocardial infarction
27. Clinical effects of beta adrenergic blockade in chronic heart failure. A meta-analysis of double-blind placebo-controlled, randomised trials
28. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial
29. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
30. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: The CAPRICORN randomised trial
31. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme
32. Prophylaxis for patients who have experienced a myocardial infarction: Drug treatment, cardiac rehabilitation and dietary manipulation: Evidence-based clinical practice guideline
33. Health and economic benefits of increased beta-blocker use following myocardial infarction
34. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100 000 patients in randomised trials
35. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: A systematic overview of data from individual patients
36. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
37. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Systematic overview of individual data from 96712 randomised patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group
38. Dietary lipids and blood cholesterol: A quantitative meta-analysis of metabolic ward studies
39. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects
40. Epidemiology of hyperglycaemia and atherosclerosis
41. The presence of multiple diabetes-related complications
42. Mortality from coronary heart disease in subjects with and without prior myocardial infarction
43. Efficacy of beta blockade, thrombolytic therapy and coronary angioplasty in diabetic patients with coronary artery disease
44. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Register Study Group
45. Undiagnosed NIDDM: Clinical and public health issues
46. Hyperglycaemia and cardiovascular disease in type 2 diabetes
47. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: Results from the San Antonio Heart Study
48. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
49. Antihypertensive therapy in preventing cardiovascular complications in people with diabetes mellitus
50. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
51. Screening for diabetes: Clinical practice recommendations: Position statement
52. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23)
53. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
54. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
55. Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group
56. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events
57. Acute effect of cigarette smoking on the coronary circulation: Constriction of epicardial and resistance vessels
58. Fibrinogen, cigarette smoking, and the risk of cardiovascular disease: Insights from the Framingham Study
59. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease
60. Acute platelet activation induced by smoking: In vivo and ex vivo studies in humans
61. Nicotine effects on eicosanoid formation and hemostatic function: Comparison of transdermal nicotine and cigarette smoking
62. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease: Results from the CASS registry
63. Effect of smoking cessation on mortality after myocardial infarction: Meta-analysis of cohort studies
64. Smoking cessation after myocardial infarction: Effects of a nurse-managed intervention
65. Smoking cessation after myocardial infarction: The effects of exercise training
66. Predictors of smoking cessation after coronary artery bypass graft surgery: Results of a randomised trial with 5-year follow-up
67. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease
68. Nicotine replacement therapy for patients with coronary artery disease
69. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report
70. Obesity
71. Weight, weight change, and coronary heart disease in women: Risk within the normal weight range
72. Body weight and mortality among women
73. Guidelines for healthy weight
74. Weight change and diabetes incidence: Findings from a national cohort of US adults
75. Weight as a risk factor for clinical diabetes in women
76. Body mass index and metabolic risk factors for coronary heart disease in women
77. What is the optimal weight for cardiovascular health?
78. Statement on cardiac rehabilitation programs
79. Exercise-based rehabilitation for coronary heart disease
80. Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction: Diet and Reinfarction Trial (DART)
81. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease
82. Dietary fat intake and prevention of cardiovascular disease: Systematic review
83. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomized trial in general practice
84. Vitamin E consumption and the risk of coronary heart disease in women
85. Vitamin E consumption and the risk of coronary heart disease in men
86. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study
87. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction
88. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
89. Vitamin E supplementation and cardiovascular events in high-risk patients
90. The antioxidant paradox